Sanzyme Biologics performs a systemic review of evidence and publishes a range of health claims for
its flagship probiotic strain Bacillus coagulans SNZ 1969® with FSANZ. Standard 1.2.7 of the Food
Standards Code provides a route for the food industry to self-substantiate a food-health relationship
in order to make a general level health claim. It requires a systematic review demonstrating a causal
association between the food and the health effect.
SNZ 1969® already has USFDA GRAS (Adult & Infant), Health Canada Approval, FSSAI licence and its
manufacturing facility is registered for exports in Japan and China. With the recent claim notification
in FSANZ- SNZ 1969® is well positioned for usability in key probiotic markets across the globe.
Bacillus coagulans SNZ 1969® is backed by 30 human studies and a five-decade history of use
demonstrating its safety and efficacy. SNZ 1969®_ is scientifically studied for gut, oral and women’s
health benefits. Today, it is marketed in over 40 countries across the globe. Being a hardy natural
spore forming probiotic strain, it doesn’t require a cold chain and is used in a range of processed
food and beverage product formats.
Sanzyme Biologics is a pioneer in probiotics and has five decades of expertise in fermentation
technology. Founded in the year 1969 as Uni-Sankyo in joint venture with Sankyo, Japan. It was the
first company to manufacture and sell probiotics under the SPORLAC brand in India. Since then, it
has evolved and transformed into a global leader in shelf and process stable probiotic solutions.